Experience
Capstan Therapeutics Announces up to $2.1 Billion Acquisition by AbbVie
June 30, 2025
Cooley advised Capstan Therapeutics, a clinical-stage biotechnology company with a mission to multiply therapeutic possibilities for patients through targeted in vivo RNA technologies, on its definitive agreement to be acquired by AbbVie.
Related contacts
Related Practices & Industries
Beta Bionics Announces Upsized $234.6 Million IPO, Concurrent $17 Million Private Placement
January 31, 2025
Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.
Related contacts
Related Practices & Industries
Structure Therapeutics Announces Upsized $547.4 Million Public Offering
June 7, 2024
Cooley advised Structure Therapeutics (Nasdaq: GPCR), a global, clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, on its upsized $547.4 million underwritten public offering.
Related contacts
Related Practices & Industries
Structure Therapeutics – $185.3 Million IPO
February 9, 2023
San Francisco – February 9, 2023 – Cooley advised Structure Therapeutics, a clinical-stage global biopharmaceutical company, on its $185.3 million initial public offering, including the full exercise of the underwriters’ option to purchase additional American depositary shares. Lawyers Charlie Kim, Patrick Loofbourrow, Andrew Harline and Su Lian Lu led the Cooley team.
The offering marks the first sizable US life sciences IPO this year. Structure Therapeutics will use the proceeds to develop new oral therapies for the treatment of various diseases, including those impacting the metabolic, cardiovascular and pulmonary systems. Its lead product candidate targets Type 2 diabetes and obesity.
Structure Therapeutics aims to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages structure-based drug discovery and computational chemistry expertise, enabling it to build a pipeline of product candidates. The company currently focuses on G-protein-coupled receptors as a therapeutic target class.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
Related contacts
Related Practices & Industries
Mirum Pharmaceuticals – $92 Million Follow-on Offering
September 7, 2022
Cooley advised the issuer for Mirum Pharmaceuticals’ $92 million follow-on offering of 4,000,000 shares of common stock at a public offering price of $23 per share. Mirum is a biopharmaceutical company developing and commercializing therapies for rare and debilitating liver diseases. Partner Jason Kent led the Cooley team.